BR122018000397B8 - solvato de darifenacina, e processo para sua preparação - Google Patents

solvato de darifenacina, e processo para sua preparação

Info

Publication number
BR122018000397B8
BR122018000397B8 BR122018000397A BR122018000397A BR122018000397B8 BR 122018000397 B8 BR122018000397 B8 BR 122018000397B8 BR 122018000397 A BR122018000397 A BR 122018000397A BR 122018000397 A BR122018000397 A BR 122018000397A BR 122018000397 B8 BR122018000397 B8 BR 122018000397B8
Authority
BR
Brazil
Prior art keywords
bladder
urinary
treatment
neurogenic
urgency
Prior art date
Application number
BR122018000397A
Other languages
English (en)
Portuguese (pt)
Other versions
BR122018000397B1 (pt
Inventor
O'oconnor Garry
George Matthews John
James Dunn Peter
Jack Newbury Trevor
Original Assignee
Aspen Global Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9933731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR122018000397(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aspen Global Incorporated filed Critical Aspen Global Incorporated
Publication of BR122018000397B1 publication Critical patent/BR122018000397B1/pt
Publication of BR122018000397B8 publication Critical patent/BR122018000397B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR122018000397A 2002-03-26 2003-03-17 solvato de darifenacina, e processo para sua preparação BR122018000397B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0207104.1 2002-03-26
GBGB0207104.1A GB0207104D0 (en) 2002-03-26 2002-03-26 Stable hydrate of a muscarinic receptor antagonist
PCT/IB2003/001043 WO2003080599A1 (en) 2002-03-26 2003-03-17 Stable hydrate of a muscarinic receptor antagonist
BRPI0308706 2003-03-17

Publications (2)

Publication Number Publication Date
BR122018000397B1 BR122018000397B1 (pt) 2019-07-02
BR122018000397B8 true BR122018000397B8 (pt) 2021-07-27

Family

ID=9933731

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122018000397A BR122018000397B8 (pt) 2002-03-26 2003-03-17 solvato de darifenacina, e processo para sua preparação
BRPI0308706A BRPI0308706B8 (pt) 2002-03-26 2003-03-17 hidrato de darifenacina, e processo para sua preparação

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0308706A BRPI0308706B8 (pt) 2002-03-26 2003-03-17 hidrato de darifenacina, e processo para sua preparação

Country Status (22)

Country Link
US (3) US6930188B2 (enExample)
EP (2) EP1490357B1 (enExample)
JP (2) JP2005524678A (enExample)
KR (4) KR20100101182A (enExample)
CN (1) CN100345840C (enExample)
AR (1) AR042608A1 (enExample)
AT (1) ATE495169T1 (enExample)
AU (1) AU2003209921A1 (enExample)
BR (2) BR122018000397B8 (enExample)
CA (1) CA2480287C (enExample)
CY (2) CY1111200T1 (enExample)
DE (1) DE60335711D1 (enExample)
DK (2) DK1490357T3 (enExample)
ES (2) ES2394067T3 (enExample)
GB (1) GB0207104D0 (enExample)
PA (1) PA8569701A1 (enExample)
PT (2) PT2336124E (enExample)
SI (2) SI2336124T1 (enExample)
SV (1) SV2003001515A (enExample)
TW (1) TW200306816A (enExample)
UY (1) UY27735A1 (enExample)
WO (1) WO2003080599A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
EP1874292A2 (en) * 2005-04-24 2008-01-09 Wyeth Methods for modulating bladder function
US20070197630A1 (en) 2005-12-27 2007-08-23 Valeriano Merli Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof
WO2008100651A2 (en) * 2007-01-05 2008-08-21 Dr. Reddy's Laboratories Ltd. Preparation of darifenacin and its salts
ES2554646T3 (es) * 2007-02-23 2015-12-22 Theravance Biopharma R&D Ip, Llc Compuestos de difenilmetilo de amonio cuaternario, de utilidad como antagonistas de receptores muscarínicos
WO2008144602A1 (en) * 2007-05-18 2008-11-27 Auspex Pharmaceuticals, Inc. Deuterated zamifenacin derivatives
WO2009007853A2 (en) * 2007-06-08 2009-01-15 Actavis Group Ptc Ehf Novel polymorphs of darifenacin free base and its hydrobromide salt
US20090005431A1 (en) * 2007-06-30 2009-01-01 Auspex Pharmaceuticals, Inc. Substituted pyrrolidines
AR068322A1 (es) * 2007-07-13 2009-11-11 Medichem Sa Forma amorfa de hidrobromuro de darifenacina y procedimientos para su preparacion
CZ300895B6 (cs) * 2008-01-28 2009-09-02 Zentiva, A. S. Zpusob prípravy Darifenacinu
WO2009125426A2 (en) * 2008-02-08 2009-10-15 Neuland Laboratories Ltd NOVEL PROCESS FOR THE PREPARATION OF (3SM-[2-(2 J-DIHYDRO-5- BENZOFURANYLϊETHYL]-α.α -DIPHENYL-3-PYRROLIDINEACETAMIDE HYDROBROMIDE
CN101983187A (zh) 2008-04-02 2011-03-02 株式会社钟化 (s)-3-(1-氰基-1，1-二苯基甲基)吡咯烷的制备方法
US20110144354A1 (en) * 2008-09-22 2011-06-16 Watson Pharma Private Limited Process for Preparation of Darifenacin and Intermediates Used in the Process
EP2236509A1 (en) 2009-04-01 2010-10-06 Ragactives, S.L. Method for obtaining 1,3-difunctionalized pyrrolidine derivatives
WO2011070419A1 (en) 2009-12-10 2011-06-16 Aurobindo Pharma Limited An improved process for the preparation of darifenacin hydrobromide
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
CA3006764A1 (en) * 2015-12-14 2017-06-22 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of gastrointestinal sphincter dysfunction
ES2815023T3 (es) * 2016-08-12 2021-03-29 Bayer Cropscience Ag Procedimiento para preparar derivados de estireno sustituidos
WO2019053051A1 (en) * 2017-09-12 2019-03-21 Lts Lohmann Therapie-Systeme Ag MICRO NEEDLE IONTOPHORESIS DEVICE

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906166D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
US5233053A (en) * 1989-03-17 1993-08-03 Pfizer Inc. Pyrrolidine derivatives
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9400600D0 (en) 1994-01-14 1994-03-09 Pfizer Ltd Treatment of motion seckness
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9612710D0 (en) * 1996-06-18 1996-08-21 Pfizer Ltd Method of treatment
AU4421697A (en) * 1996-09-19 1998-04-14 American Home Products Corporation Method of treating urinary incontinence
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist

Also Published As

Publication number Publication date
PT2336124E (pt) 2012-12-12
ES2358644T3 (es) 2011-05-12
KR101212908B1 (ko) 2012-12-14
KR20120098888A (ko) 2012-09-05
WO2003080599A1 (en) 2003-10-02
JP2010195828A (ja) 2010-09-09
EP1490357B1 (en) 2011-01-12
ATE495169T1 (de) 2011-01-15
AR042608A1 (es) 2005-06-29
SV2003001515A (es) 2003-12-15
US7696357B2 (en) 2010-04-13
KR20100101182A (ko) 2010-09-16
DK1490357T3 (da) 2011-04-04
KR20110130539A (ko) 2011-12-05
SI1490357T1 (sl) 2011-05-31
US20030191176A1 (en) 2003-10-09
DE60335711D1 (de) 2011-02-24
PT1490357E (pt) 2011-03-01
TW200306816A (en) 2003-12-01
UY27735A1 (es) 2003-10-31
GB0207104D0 (en) 2002-05-08
BRPI0308706B8 (pt) 2021-05-25
CN1642945A (zh) 2005-07-20
DK2336124T3 (da) 2012-12-17
US20080167367A1 (en) 2008-07-10
BRPI0308706B1 (pt) 2018-07-10
EP2336124B1 (en) 2012-08-29
SI2336124T1 (sl) 2012-12-31
PA8569701A1 (es) 2003-12-10
US20050245597A1 (en) 2005-11-03
CY1111200T1 (el) 2015-06-11
KR101026283B1 (ko) 2011-03-31
US6930188B2 (en) 2005-08-16
KR20040093477A (ko) 2004-11-05
JP2005524678A (ja) 2005-08-18
CY1113433T1 (el) 2016-06-22
EP1490357A1 (en) 2004-12-29
EP2336124A1 (en) 2011-06-22
CN100345840C (zh) 2007-10-31
CA2480287C (en) 2011-05-31
HK1156626A1 (en) 2012-06-15
ES2394067T3 (es) 2013-01-16
AU2003209921A1 (en) 2003-10-08
BR122018000397B1 (pt) 2019-07-02
HK1080847A1 (zh) 2006-05-04
CA2480287A1 (en) 2003-10-02
BR0308706A (pt) 2005-01-04

Similar Documents

Publication Publication Date Title
BR122018000397B8 (pt) solvato de darifenacina, e processo para sua preparação
Remington et al. Treating negative symptoms in schizophrenia: an update
MA31004B1 (fr) Dispersion solide d'un antagoniste de la neurokinine
AR066016A1 (es) Uso de un inhibidor del tnf alfa junto con una antihistamina para tratar la rinitis alergica y la conjuntivitis alergica
Kumar et al. Comparison of the effect of diclofenac with hyoscine‐N‐butylbromide in the symptomatic treatment of acute biliary colic
MA30556B1 (fr) COMPOSES A BASE DE DIALKYLPHENYLE AYANT UNE ACTIVITE AGONISTE DU RECEPTEUR ADRENERGIQUE ß2 ET ANTAGONISTE DU RECEPTEUR MUSCARINIQUE.
EP2268647A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE IDENTIFICATION AND TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES
BRPI0510971A (pt) composto ou um sal farmacologicamente aceitável do mesmo, e, composição farmacêutica
WO2007117557A3 (en) Diaminopropanol renin inhibitors
Fernandez-Bolanos et al. Butyrylcholinesterase inhibitors as potential anti-Alzheimer’s agents: an updated patent review (2018-present)
BRPI0413693A (pt) composição farmacêutica para a prevenção e tratamento da viciação em um mamìfero
EP2365974A4 (en) FLUORATED BENZOTHIAZOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND IMAGE-DISPLAYING AGENT FOR THE DIAGNOSIS OF ALZHEIMER DISEASE, WHICH USES THEREOF
US20060173052A1 (en) Use of the non-opiate analgesic drug flupirtine of the treatment of overactive bladder and associated diseases including urge incontinence, urinary flow problems as a result of prostate hyperplasia and irritable bowl syndrome
MX2024010789A (es) Polimorfos de un inhibidor de dihidroorotato deshidrogenasa (dhod)
CN101903021A (zh) 用于治疗精神病的α-氨基酰胺衍生物
CA3073801A1 (en) Compositions and methods for ameliorating pain
Kotani et al. The atypical antipsychotic blonanserin reverses (+)-PD-128907-and ketamine-induced deficit in executive function in common marmosets
Pournasiri et al. Relationship of generalized joint hypermobility with vesicoureteral reflux and urinary tract infection
EP2318038A4 (en) THERAPEUTIC AGENT FOR TREATING LOWER DISEASE DISEASE AND MEANS FOR IMPROVING SYMPTOM IN LOWER HARVES
EP1897867A4 (en) COMPOUNDS, MANUFACTURING METHOD AND APPLICATIONS THEREFOR FOR INTERRUPTING THE RECOVERY OF 5-HYDROXYTRYPTAMINE AND NOREPINEPHRINE OR FOR THE TREATMENT OF DISEASES SUCH AS DEPRESSION AND AID.
DOP2003000615A (es) Hidrato estable de un antagonista de receptores muscarinicos
EP2025342A4 (en) THERAPEUTIC AGENT OR DEVELOPMENT INHIBITOR OF POLYGLUTAMINE DISEASE
Boulin et al. Neurological damage from recreational nitrous oxide use: Two distinct electroclinical profiles in a retrospective cohort
ATE531370T1 (de) Piperidine-derivate zur behandlung von inkontinenzen
Jain et al. Recent developments on anti-convulsants

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/07/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/07/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/03/2003, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 17/03/2023